Mastering the correct injection technique is a fundamental skill for anyone using GLP-1 receptor agonist medications such as Wegovy (semaglutide) or Zepbound (tirzepatide). These medications are administered as subcutaneous injections — delivered into the fatty tissue just beneath the skin rather than into muscle or a vein. Correct technique ensures that the full dose is delivered reliably, minimizes discomfort and bruising, and helps prevent skin complications at injection sites.
Approved Injection Sites: Where to Inject
Both Wegovy and Zepbound can be injected into three approved anatomical regions. Each site has advantages and considerations:
- Abdomen (most commonly used): The area of the abdomen at least 5 centimeters (2 inches) away from the navel. The abdomen has the most generous subcutaneous fat layer in most individuals and offers the most consistent drug absorption. It is also the most accessible site for self-injection. Avoid the area immediately around the belly button (umbilicus), where the skin is thicker and less vascular.
- Anterior thigh (front of thigh): The upper and outer quadrant of the thigh is the preferred thigh site. This location is easily accessible and comfortable for self-injection. Avoid the inner thigh (risk of injecting into muscle or blood vessels) and the area behind the knee.
- Upper outer arm: The posterior-lateral aspect of the upper arm, approximately halfway between the shoulder and elbow. This site is generally less accessible for self-injection without a helper or mirror and is more commonly used by caregivers administering the medication. If self-injecting into the upper arm, a rotation technique that allows you to pinch the skin adequately is important.
The FDA prescribing information specifies that all three sites are acceptable and that the medication should not be injected into the same specific spot on consecutive injections. Patients may use the same body region (e.g., abdomen) each week but should rotate the precise injection location within that region.
Site Rotation: Why It Matters
Injection site rotation is a critical practice that prevents a condition called lipohypertrophy — an abnormal accumulation of fatty tissue at a repeatedly injected site. Lipohypertrophy looks and feels like a rubbery lump under the skin and results from the repeated trauma and growth-stimulating effects of medications at a single site. Repeated injections into the exact same spot can cause local skin changes that impair drug absorption and increase discomfort.
A practical rotation approach for the abdomen is to divide it into quadrants (upper-left, upper-right, lower-left, lower-right) and cycle through these areas on successive injections. For example: week 1 in the upper-left abdomen, week 2 in the upper-right, week 3 in the lower-right, week 4 in the lower-left, and then repeating. This ensures at least 4 weeks of rest for any given spot.
Step-by-Step Injection Procedure
Follow these steps for each weekly injection:
- Step 1 — Prepare the medication: Remove the pen from the refrigerator at least 15–30 minutes before injection. Cold medication causes more stinging on injection. Inspect the solution through the pen window; it should be clear and colorless. Do not use if it appears cloudy, colored, or contains visible particles.
- Step 2 — Wash your hands: Thoroughly wash and dry your hands with soap and water before handling the pen or injection site.
- Step 3 — Select and clean the injection site: Choose a site in one of the three approved areas. Clean the skin with an alcohol swab and allow it to dry completely. Injecting before the alcohol dries can cause stinging.
- Step 4 — Prepare the pen: Remove the pen cap as directed in the Instructions for Use. Both Wegovy and Zepbound use auto-injector pen devices — no needle attachment is required by the user. Check that the correct dose window is displayed. Do not shake the pen.
- Step 5 — Inject: Hold the pen firmly against the skin at a 90-degree angle. Press and hold the injection button firmly. You will hear or feel a click indicating the injection has started. Hold the pen in place for the full counting period specified (typically 5–10 seconds for each pen type) to ensure the full dose is delivered.
- Step 6 — Remove and dispose: Lift the pen away from the skin after the full hold time. A small red indicator or window change typically signals that the injection is complete. Dispose of the used pen in an approved sharps container — do not recap or place in regular household waste.
💡 💡 Clinical Pearl
The most common injection error is removing the pen from the skin too quickly — before the full dose has been delivered. The auto-injector mechanism requires several seconds to complete delivery after the initial click. If the pen is pulled away too soon, part of the dose may be expelled onto the skin or remain in the device rather than being absorbed. Always count to at least 5–10 seconds (per your specific pen’s instructions) while maintaining firm skin contact before removing the device. If you see liquid on the skin after removing the pen, do not attempt to re-inject — contact your pharmacist or prescriber for guidance on whether a repeat dose is needed.
Common Patient Mistakes and How to Avoid Them
- Injecting cold medication: Can cause unnecessary stinging and injection site reactions. Always allow the pen to reach room temperature before use.
- Not rotating sites: Leads to lipohypertrophy and inconsistent drug absorption. Follow a systematic rotation plan.
- Injecting into areas of active skin irritation: Avoid injecting into areas of redness, bruising, scarring, or tattoos. These areas have altered skin structure that may affect absorption.
- Not cleaning the skin properly: Introduces infection risk. Always use a fresh alcohol swab and allow the site to dry.
- Pressing too hard or at an angle: May cause the pen to miss the subcutaneous layer. Hold the pen perpendicularly at 90 degrees and press firmly but without excessive force.
- Skipping the hold time: As described above, the most consequential error for dose delivery accuracy.
Pain Management at Injection Sites
Most patients find GLP-1 RA injections minimally painful, particularly as they develop confidence with the technique. Strategies to minimize discomfort include: allowing medication to warm to room temperature, ensuring the alcohol prep site is fully dry, injecting at a consistent 90° angle, relaxing the muscles at the injection site, and using a new site each week. Mild bruising or small erythematous (red) spots at the injection site are common and typically resolve within a few days without treatment.
For information on correct storage of the pen between injections, see Proper Storage and Handling of GLP-1 RA Pens. For guidance on beginning your dosing journey, see Step-by-Step Dosing and Titration Guide.
💡 Frequently Asked Questions (FAQ)
Q1: Can I inject into the same area every week if I just move to a different spot within it?
A1: Yes. For example, you may use the abdomen every week as long as you systematically rotate the precise injection location within the abdominal area, ensuring each specific spot gets adequate rest between injections. Using different sites within the same region is acceptable; always injecting into one tiny spot is not.
Q2: What should I do if I accidentally inject into a blood vessel or see blood?
A2: Inadvertent intravascular injection with a subcutaneous pen device is extremely rare given the short needle length and subcutaneous target. A small drop of blood at the injection site after withdrawal is common and not concerning. Apply gentle pressure with a clean swab. If you notice significant bleeding or have concerns, contact your healthcare provider.
Q3: I have very little belly fat — should I still inject in the abdomen?
A3: Lean patients with minimal abdominal fat can still use the abdomen, but should use the pinch-up technique: gently pinch and lift a fold of skin before injecting, to create enough subcutaneous tissue depth for the needle. The thigh is often an easier site for lean individuals. Your prescriber or nurse can demonstrate the pinch-up technique at your next appointment.
📚 References & Sources
- FDA. (2021). Prescribing Information: Wegovy (semaglutide) injection 2.4 mg. U.S. Food and Drug Administration.
- FDA. (2023). Prescribing Information: Zepbound (tirzepatide) injection. U.S. Food and Drug Administration.
- Müller, T.D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130.